Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06639854 · ClinicalTrials.gov registry record · NA
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
A NA study of Hematopoietic Cell Transplant and Cytomegalovirus Cell Mediated Immunity, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT06639854 is a NA study of Hematopoietic Cell Transplant and Cytomegalovirus Cell Mediated Immunity that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 105 participants, below the 372-participant average among 6 other Hematopoietic Cell Transplant trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06639854, a NA study of Hematopoietic Cell Transplant and Cytomegalovirus Cell Mediated Immunity, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.
Conditions Studied
Interventions
- DRUG Letermovir
- PROCEDURE Hematopoietic Cell Transplant
Study Locations (1)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06639854
The ClinicalTrials.gov registry entry for NCT06639854 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 372-participant average among 6 other Hematopoietic Cell Transplant trials with a reported enrollment target (72% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic Cell Transplant appearing as the primary indexed condition, and to 2 interventions - of which Letermovir is the first listed.
NCT06639854 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06639854 about?
NCT06639854 is a clinical study titled "The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients". The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.
What is the current status of trial NCT06639854?
This trial is currently recruiting. It is a NA study. The enrollment target is 105 participants. The study started on 2024-11-20. Estimated completion is 2026-12-31.
What conditions does trial NCT06639854 study?
This clinical trial studies the following conditions: Hematopoietic Cell Transplant, Cytomegalovirus Cell Mediated Immunity.
What interventions are being tested in trial NCT06639854?
The interventions under investigation include: Letermovir (DRUG), Hematopoietic Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT06639854?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06639854 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Cell Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
Virtual Rehabilitation in HCT
RECRUITING · NA
-
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
RECRUITING · Phase 2
-
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
RECRUITING
-
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
ACTIVE NOT RECRUITING
-
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
COMPLETED
Explore more on PlainTrial
Hematopoietic Cell Transplant
All registered trials for this condition
Cytomegalovirus Cell Mediated Immunity
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.